Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Cash & Current Investments (2024 - 2025)

Caris Life Sciences has reported Cash & Current Investments over the past 2 years, most recently at $799.3 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $799.3 million for Q4 2025, up 1081.68% from a year ago — trailing twelve months through Dec 2025 was $799.3 million (up 1081.68% YoY), and the annual figure for FY2025 was $799.3 million, up 1081.68%.
  • Cash & Current Investments for Q4 2025 was $799.3 million at Caris Life Sciences, up from $756.3 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for CAI hit a ceiling of $799.3 million in Q4 2025 and a floor of $67.6 million in Q4 2024.